{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:59:50Z","timestamp":1785473990008,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Total Neoadjuvant Therapy (TNT) is increasingly replacing standard chemoradiotherapy (sCRT) for the treatment of locally advanced rectal cancer (LARC). Data on the use of personalized TNT (pTNT) regimens tailored to patient disease characteristics remain scarce. Accordingly, this study aimed to assess long-term outcomes of pTNT in patients with LARC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a secondary analysis of a multicentre retrospective cohort study. Patients treated with pTNT between 2019 and 2022 were compared to a historical cohort from the WAIT trial (2012\u20132014), which included extended chemotherapy during the interval period (xCRT) or sCRT followed by adjuvant chemotherapy. The main outcomes were 4-year disease-free survival (DFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty patients treated with pTNT were matched with 49 patients from the WAIT trial (25 xCRT, 24 sCRT). All WAIT trial patients underwent surgery, whereas 27 (67.5%) pTNT patients underwent surgery and 13 (32.5%) were managed non-operatively. Median follow-up was 48 months. No significant differences were observed in 4-year DFS (pTNT 70% vs. xCRT 68% vs. sCRT 75%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.764) or OS (pTNT 82.5% vs. xCRT 80% vs. sCRT 83.3%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.907). Within the pTNT group, patients with an oCR had significantly higher OS compared to those without oCR (95.2% vs. 68.4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.021).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that pTNT achieves comparable survival outcomes to xCRT and sCRT in patients with LARC, despite higher rates of non-operative management. These findings should be interpreted cautiously given the exploratory nature of the analysis and limited sample size. Larger studies with longer follow-up are required to validate these early data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12029-026-01551-6","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:01:06Z","timestamp":1785423666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Four-Year Survival Outcomes of Personalized Total Neoadjuvant Therapy Versus Chemotherapy During the \u2018Wait Period\u2019 Versus Standard Chemoradiotherapy for Locally Advanced Rectal Cancer"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-625X","authenticated-orcid":false,"given":"Sergei","family":"Bedrikovetski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-3857","authenticated-orcid":false,"given":"Zachary","family":"Bunjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5598-6397","authenticated-orcid":false,"given":"Ishraq","family":"Murshed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-8871","authenticated-orcid":false,"given":"Tarik","family":"Sammour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"1551_CR1","doi-asserted-by":"publisher","first-page":"103015","DOI":"10.1016\/j.ctrv.2025.103015","volume":"140","author":"M Airoldi","year":"2025","unstructured":"Airoldi M, Rosello S, Tarazona N, Huerta M, Perez-Santiago L, Fleitas T, et al. Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life. Cancer Treat Rev. 2025;140:103015. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103015.","journal-title":"Cancer Treat Rev"},{"issue":"15","key":"1551_CR2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","volume":"40","author":"J Jin","year":"2022","unstructured":"Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022;40(15):1681\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01667.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1551_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):873\u201381. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.019.","journal-title":"Ann Oncol"},{"issue":"4","key":"1551_CR4","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","volume":"278","author":"EA Dijkstra","year":"2023","unstructured":"Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766\u201372. https:\/\/doi.org\/10.1097\/SLA.0000000000005799.","journal-title":"Ann Surg"},{"issue":"4","key":"1551_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa2303269","volume":"389","author":"D Schrag","year":"2023","unstructured":"Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322\u201334. https:\/\/doi.org\/10.1056\/NEJMoa2303269.","journal-title":"N Engl J Med"},{"issue":"25","key":"1551_CR6","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","journal-title":"N Engl J Med"},{"issue":"7","key":"1551_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/OP.21.00114","volume":"17","author":"EH Balagamwala","year":"2021","unstructured":"Balagamwala EH, Gorgun E, Khorana AA. Future of Personalized Multimodality Management of Locally Advanced Rectal Cancer. JCO Oncol Pract. 2021;17(7):403\u20134. https:\/\/doi.org\/10.1200\/OP.21.00114.","journal-title":"JCO Oncol Pract"},{"key":"1551_CR8","doi-asserted-by":"publisher","unstructured":"Pakvisal N, Pappas L, Caughey BA, Ricciardi R, Parikh A. Personalized treatment modalities for rectal cancer: advances in neoadjuvant treatment. J Clin Med. 2025;14(13). https:\/\/doi.org\/10.3390\/jcm14134411.","DOI":"10.3390\/jcm14134411"},{"issue":"1\u20132","key":"1551_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/ans.18021","volume":"93","author":"S Bedrikovetski","year":"2023","unstructured":"Bedrikovetski S, Fitzsimmons T, Perry J, Vather R, Carruthers S, Selva-Nayagam S, et al. Personalized total neoadjuvant therapy (pTNT) for advanced rectal cancer with tailored treatment sequencing based on clinical stage at presentation. ANZ J Surg. 2023;93(1\u20132):173\u201381. https:\/\/doi.org\/10.1111\/ans.18021.","journal-title":"ANZ J Surg"},{"issue":"5","key":"1551_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/ans.18229","volume":"93","author":"S Bedrikovetski","year":"2023","unstructured":"Bedrikovetski S, Traeger L, Fitzsimmons T, Perry J, Vather R, Moore JW, et al. Personalized total neoadjuvant therapy versus chemotherapy during the \u2018wait period\u2019 versus standard chemoradiotherapy for locally advanced rectal cancer. ANZ J Surg. 2023;93(5):1267\u201373. https:\/\/doi.org\/10.1111\/ans.18229.","journal-title":"ANZ J Surg"},{"issue":"11","key":"1551_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/codi.13724","volume":"19","author":"J Moore","year":"2017","unstructured":"Moore J, Price T, Carruthers S, Selva-Nayagam S, Luck A, Thomas M, et al. Prospective randomized trial of neoadjuvant chemotherapy during the \u2018wait period\u2019 following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Dis. 2017;19(11):973\u20139. https:\/\/doi.org\/10.1111\/codi.13724.","journal-title":"Colorectal Dis"},{"key":"1551_CR12","volume-title":"Clinical practice guidelines for surveillance colonoscopy","author":"R Leong","year":"2022","unstructured":"Leong R, Corte C, Koh C, Wu B, Kariyawasam V, Chetcuti A. Clinical practice guidelines for surveillance colonoscopy. Sydney: Cancer Council Australia; 2022."},{"issue":"23","key":"1551_CR13","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1200\/jco.22.00032","volume":"40","author":"J Garcia-Aguilar","year":"2022","unstructured":"Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546\u201356. https:\/\/doi.org\/10.1200\/jco.22.00032.","journal-title":"J Clin Oncol"},{"key":"1551_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eclinm.2019.09.009","volume":"16","author":"S Zhu","year":"2019","unstructured":"Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, et al. Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. EClinicalMedicine. 2019;16:23\u20139. https:\/\/doi.org\/10.1016\/j.eclinm.2019.09.009.","journal-title":"EClinicalMedicine"},{"issue":"5","key":"1551_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/oncolo\/oyac025","volume":"27","author":"JK Kim","year":"2022","unstructured":"Kim JK, Marco MR, Roxburgh CSD, Chen CT, Cercek A, Strombom P, et al. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Oncologist. 2022;27(5):380\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyac025.","journal-title":"Oncologist"},{"issue":"10","key":"1551_CR16","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/DCR.0000000000001207","volume":"61","author":"MR Marco","year":"2018","unstructured":"Marco MR, Zhou L, Patil S, Marcet JE, Varma MG, Oommen S, et al. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial. Dis Colon Rectum. 2018;61(10):1146\u201355. https:\/\/doi.org\/10.1097\/DCR.0000000000001207.","journal-title":"Dis Colon Rectum"},{"issue":"5","key":"1551_CR17","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"T Conroy","year":"2021","unstructured":"Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00079-6.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1551_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):873\u201381. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.019.","journal-title":"Ann Oncol"},{"key":"1551_CR19","doi-asserted-by":"publisher","first-page":"102796","DOI":"10.1016\/j.ctrv.2024.102796","volume":"129","author":"J Socha","year":"2024","unstructured":"Socha J, Glynne-Jones R, Bujko K. Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review. Cancer Treat Rev. 2024;129:102796. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102796.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1551_CR20","doi-asserted-by":"publisher","first-page":"e2350903","DOI":"10.1001\/jamanetworkopen.2023.50903","volume":"7","author":"HM Thompson","year":"2024","unstructured":"Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Verheij FS, et al. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2350903. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50903.","journal-title":"JAMA Netw Open"},{"key":"1551_CR21","doi-asserted-by":"publisher","first-page":"101120","DOI":"10.1016\/j.ctro.2026.101120","volume":"58","author":"GW Wurschi","year":"2026","unstructured":"Wurschi GW, Schneider M, Becker JN, Frerker B, Vorbach SM, Ehret F, et al. Clinical and treatment-related predictors of complete response after total neoadjuvant therapy for rectal cancer in a large multicenter analysis. Clin Transl Radiat Oncol. 2026;58:101120. https:\/\/doi.org\/10.1016\/j.ctro.2026.101120.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1551_CR22","doi-asserted-by":"publisher","unstructured":"Banken E, Geubels BM, Vande Kerckhove FEC, Creemers DMJ, Ketelaers SHJ, Nederend J, et al. Watch-and-wait approach in high-risk locally advanced rectal cancer: outcomes after complete response to total neoadjuvant therapy. BJS Open. 2025;9(6). https:\/\/doi.org\/10.1093\/bjsopen\/zraf136.","DOI":"10.1093\/bjsopen\/zraf136"},{"issue":"5","key":"1551_CR23","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.annonc.2025.01.006","volume":"36","author":"H Williams","year":"2025","unstructured":"Williams H, Fokas E, Diefenhardt M, Lee C, Verheij FS, Omer DM, et al. Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO\/ARO\/AIO-12 and OPRA randomized phase II trials. Ann Oncol. 2025;36(5):543\u20137. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.006.","journal-title":"Ann Oncol"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"114291","DOI":"10.1016\/j.ejca.2024.114291","volume":"210","author":"E Fokas","year":"2024","unstructured":"Fokas E, Williams H, Diefenhardt M, Lin S, Qin LX, Piso P, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO\/ARO\/AIO-12 and the OPRA randomized phase 2 trials. Eur J Cancer. 2024;210:114291. https:\/\/doi.org\/10.1016\/j.ejca.2024.114291.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1551_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12885-025-13664-5","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, Gao Y, Zhang C, Wu Y, Wang Q, Chen W, et al. Prognostic significance of preoperative CT-based sarcopenia in locally advanced rectal cancer: a multicenter retrospective study. BMC Cancer. 2025;25(1):261. https:\/\/doi.org\/10.1186\/s12885-025-13664-5.","journal-title":"BMC Cancer"},{"issue":"7","key":"1551_CR26","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1245\/s10434-023-13225-9","volume":"30","author":"HM Thompson","year":"2023","unstructured":"Thompson HM, Bates DDB, Pernicka JG, Park SJ, Nourbakhsh M, Fuqua JL, et al. MRI Assessment of Extramural Venous Invasion Before and After Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer and Its Association with Disease-Free and Overall Survival. Ann Surg Oncol. 2023;30(7):3957\u201365. https:\/\/doi.org\/10.1245\/s10434-023-13225-9.","journal-title":"Ann Surg Oncol"},{"key":"1551_CR27","doi-asserted-by":"publisher","first-page":"116199","DOI":"10.1016\/j.ejca.2025.116199","volume":"234","author":"P Maerten","year":"2026","unstructured":"Maerten P, Defraene G, Wolthuis A, Schraepen C, Bislenghi G, De Hertogh G, et al. Long-term recurrence patterns in rectal cancer after neoadjuvant therapy: 25-years of real-world data. Eur J Cancer. 2026;234:116199. https:\/\/doi.org\/10.1016\/j.ejca.2025.116199.","journal-title":"Eur J Cancer"},{"issue":"19","key":"1551_CR28","doi-asserted-by":"publisher","first-page":"e70291","DOI":"10.1002\/cam4.70291","volume":"13","author":"R Ghalehtaki","year":"2024","unstructured":"Ghalehtaki R, Nourbakhsh F, Abyaneh R, Sharifian A, Pashapour-Khoyi S, Aghili M, et al. Optimal Sequence for Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: An Evidence-Based Review. Cancer Med. 2024;13(19):e70291. https:\/\/doi.org\/10.1002\/cam4.70291.","journal-title":"Cancer Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01551-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01551-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:30:55Z","timestamp":1785472255000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01551-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01551-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Central Adelaide Local Health Network (HREC\/15\/RAH\/186) and St. Andrew\u2019s Hospital Human Research Ethics Committee (#117). As this secondary analysis involved the retrospective collection of survival data from a previously published cohort, a waiver of informed consent was granted by our ethics committee.","order":1,"name":"Ethics","label":"Ethical and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"171"}}